Relmada Therapeutics Inc (RLMD) Stock Price, Quote & News

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 629 1376

Website: www.relmada.com

Address:

2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States

VikaDelic Jan. 14 at 8:12 PM

$RLMD insider buys, fastest FDA path just confirmed for onc asset, psychedelic wt loss data before long. ⏰

0 · Reply

teaman60 Jan. 14 at 5:49 PM

$RLMD this has almost no upside unless there is a buyout of their science.

0 · Reply

teaman60 Jan. 14 at 3:24 AM

$RLMD Heading into the high 2s by Feb. Company burning cash with zero revenues. Not a chance their drug ever gets to the market without a buyout

0 · Reply

TheRealShortSqueezy Jan. 13 at 5:24 PM

🚀 The Wildest Small-Caps Runners of 2025 While most eyes stayed on megacaps, these names delivered massive calendar-year gains, from triple-digit movers to near 20 baggers. 📊2025 Performance (Under 300M market cap) 1. $FIEE (FIE) 🟰 +1,950.00% 2. $DBGI (Digital Brands Group) 🟰 +1,112.70% 3. $RLMD (Relmada Therapeutics) 🟰 +871.24% 4. $XWIN.X (XMax) 🟰 +850.81% 5. $SOGP (Sound Group) 🟰 +847.42% 6. TII (Titan Mining) 🟰 +819.77% 7. DFDV (DeFi Development) 🟰 +797.93% 8. ZEPP (Zepp Health Corporation) 🟰 +665.20% 10. SLGL (Sol-Gel Technologies) 🟰 +467.09% 11. BLBX (Blackboxstocks) 🟰 +431.22% Now the focus shifts to 2026 and which names are worth watching as momentum resets.

0 · Reply

DARKP00L Jan. 12 at 12:35 PM

$RLMD 07:16 on Jan. 12 2026 Relmada Therapeutics Receives Written Feedback from FDA Regarding NDV-01 In Second-Line Refractory, High-Grade BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ #tradeideas

0 · Reply

DARKP00L Jan. 12 at 12:17 PM

0 · Reply

YGLD Jan. 10 at 8:15 PM

Biotech Phase 3 Catalyst Watchlist - Ranked By Timing ⏱️ $SLS $GOSS $OCUL $RLMD

0 · Reply

teaman60 Jan. 9 at 8:12 PM

$RLMD cash burn

0 · Reply

Icemanrush16 Jan. 9 at 4:48 PM

$AQST so a beat up BIO! I’m in $CORT $MREO $RLMD $ZBIO

0 · Reply

VikaDelic Jan. 5 at 6:36 PM

$RLMD soon enough we find out why insiders won’t stop buying. Someone accumulated this nonstop for the last two months- final shakeout unfolding… they got Teabag working overtime! 🤣

1 · Reply

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

Dec 3, 2025, 7:30 AM EST - 6 weeks ago

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Nov 13, 2025, 7:21 PM EST - 2 months ago

Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:01 PM EST - 2 months ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 2 months ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Nov 4, 2025, 7:09 AM EST - 2 months ago

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Nov 4, 2025, 7:01 AM EST - 2 months ago

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Oct 7, 2025, 7:30 AM EDT - 3 months ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Sep 16, 2025, 9:00 AM EDT - 4 months ago

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 10, 2025, 7:15 AM EDT - 4 months ago

Relmada Issues Mid-Year CEO Letter to Shareholders

Aug 8, 2025, 1:55 PM EDT - 5 months ago

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 5 months ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Jul 31, 2025, 7:00 AM EDT - 5 months ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 15, 2025, 8:00 AM EDT - 6 months ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 9, 2025, 8:00 AM EDT - 6 months ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jun 17, 2025, 7:00 AM EDT - 7 months ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

May 12, 2025, 10:02 PM EDT - 8 months ago

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 8 months ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:30 AM EDT - 8 months ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 28, 2025, 1:38 PM EDT - 9 months ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 9 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 24, 2025, 8:00 AM EDT - 9 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 14, 2025, 7:30 AM EDT - 9 months ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Mar 27, 2025, 8:07 PM EDT - 10 months ago

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 10 months ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 26, 2025, 9:00 AM EDT - 10 months ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 25, 2025, 7:30 AM EDT - 10 months ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Feb 6, 2025, 7:30 AM EST - 1 year ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Dec 9, 2024, 8:11 AM EST - 1 year ago

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 4, 2024, 2:02 PM EST - 1 year ago

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Dec 4, 2024, 8:00 AM EST - 1 year ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Nov 21, 2024, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 14, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 10, 2024, 9:39 AM EST - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:32 PM EST - 1 year ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 9, 2024, 6:25 AM EDT - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 9:45 AM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Jul 23, 2024, 3:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Jul 22, 2024, 11:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

Jul 19, 2024, 5:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Breaches And Impacted Investors Are Encouraged To Initiate Dialogues

Jul 18, 2024, 5:15 PM EDT - 1 year ago

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Violations And Urges Affected Investors To Start Conversations

Jul 17, 2024, 3:30 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Examination For Possible Securities Breaches By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate Dialogues

Jul 16, 2024, 3:45 PM EDT - 1 year ago

The Schall Law Firm Encourages Affected Investors To Start Conversation, Relmada Therapeutics Inc Is Under Scrutiny For Potential Securities Breaches

Jul 15, 2024, 3:15 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Urging Impacted Investors To Initiate Dialogue

Jul 13, 2024, 7:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Probe By The Schall Law Firm For Possible Securities Breaches Urges Affected Investors To Start Conversation

VikaDelic Jan. 14 at 8:12 PM

$RLMD insider buys, fastest FDA path just confirmed for onc asset, psychedelic wt loss data before long. ⏰

0 · Reply

teaman60 Jan. 14 at 5:49 PM

$RLMD this has almost no upside unless there is a buyout of their science.

0 · Reply

teaman60 Jan. 14 at 3:24 AM

$RLMD Heading into the high 2s by Feb. Company burning cash with zero revenues. Not a chance their drug ever gets to the market without a buyout

0 · Reply

TheRealShortSqueezy Jan. 13 at 5:24 PM

0 · Reply

DARKP00L Jan. 12 at 12:35 PM

0 · Reply

DARKP00L Jan. 12 at 12:17 PM

0 · Reply

YGLD Jan. 10 at 8:15 PM

Biotech Phase 3 Catalyst Watchlist - Ranked By Timing ⏱️ $SLS $GOSS $OCUL $RLMD

0 · Reply

teaman60 Jan. 9 at 8:12 PM

$RLMD cash burn

0 · Reply

Icemanrush16 Jan. 9 at 4:48 PM

$AQST so a beat up BIO! I’m in $CORT $MREO $RLMD $ZBIO

0 · Reply

VikaDelic Jan. 5 at 6:36 PM

$RLMD soon enough we find out why insiders won’t stop buying. Someone accumulated this nonstop for the last two months- final shakeout unfolding… they got Teabag working overtime! 🤣

1 · Reply

teaman60 Jan. 5 at 5:47 PM

$RLMD Ugly

0 · Reply

teaman60 Jan. 3 at 7:05 PM

$RLMD Jan going to bring this into the $2S, no way to avoid it. The cash burn is a killer

0 · Reply

garygb Jan. 3 at 6:45 PM

$RLMD Patience

0 · Reply

makingitnow Jan. 3 at 3:33 AM

$RLMD stopped out today at $4.30 from 1.74. may revisit

0 · Reply

teaman60 Jan. 2 at 7:02 PM

$RLMD Stay away, they can't get this over the finish line

0 · Reply

peepthestamp Jan. 2 at 4:54 PM

$RLMD - Aging Well

0 · Reply

VikaDelic Jan. 2 at 4:20 PM

$RLMD a top 10 holding in the psychedelics ETF, w/ psychedelics sector showing signs of activity heading into a pivotal year. Small float stock in a rising tides setup…

0 · Reply

signaljumper Jan. 2 at 4:15 PM

$RLMD lets See where we will Close than we have a fail breakout or a retest.

1 · Reply

teaman60 Jan. 2 at 3:59 PM

$RLMD Bad news heading for this stock. They do not have the resources to get this over the finish line and into the marketplace. A buyout is the only option

0 · Reply

teaman60 Jan. 2 at 2:39 PM

$RLMD Never ever buy this in premarket

0 · Reply

StockConsultant Jan. 2 at 2:12 PM

$RLMD Relmada Therapeutics stock, watch for a narrow range breakout, target 6.5 area

1 · Reply

makingitnow Jan. 2 at 2:03 PM

$RLMD where is everyone? Look at the chart. it doesnt get much better

0 · Reply

Market Cap	301.40M
Revenue (ttm)	0.00
Net Income (ttm)	-79.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	285,730
Avg Vol	1,392,470
Day's Range	N/A - N/A
Shares Out	73.33M
Stochastic %K	14%
Beta	0.77
Analysts	Strong Sell
Price Target	$6.67